{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:59Z","timestamp":1793191799592,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite advances in lipid-lowering treatment, atherosclerotic cardiovascular disease remains the leading cause of mortality, underscoring the need to address residual risk. Targeting both the synthesis and clearance of triglyceride (TG)-rich lipoproteins is a promising approach. Liver X receptor (LXR) repression can reduce plasma TG and cholesterol and improve insulin sensitivity by suppressing de novo lipogenesis and intestinal lipid absorption and enhancing clearance of TG-rich lipoproteins, but its clinical utility remains unexplored. Here we demonstrate the role of LXR inverse agonists in lipid metabolism and metabolic diseases in preclinical models and humans. Given concerns that systemic LXR repression may impair reverse cholesterol transport, we developed TLC-2716, an orally administered, gut- and liver-restricted LXR inverse agonist. In human liver organoids modeling steatohepatitis, TLC-2716 reduced lipid accumulation and suppressed inflammation and fibrotic gene expression. In a randomized, placebo-controlled phase 1 clinical trial, 14-day treatment with TLC-2716 was well tolerated (primary endpoints) and resulted in placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol (secondary endpoints). In conclusion, these results highlight the tolerability and therapeutic potential of TLC-2716 as a treatment for managing dyslipidemia and reducing residual atherosclerotic cardiovascular disease risk in humans. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT05483998\" ext-link-type=\"uri\">NCT05483998<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-04169-6","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:02:39Z","timestamp":1768557759000},"page":"883-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5121-9190","authenticated-orcid":false,"given":"Xiaoxu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7164-6771","authenticated-orcid":false,"given":"Giorgia","family":"Benegiamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Sroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4802-7752","authenticated-orcid":false,"given":"Ryan S.","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo V. G.","family":"von Alvensleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Kremoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6989-3041","authenticated-orcid":false,"given":"Takanori","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0312-6200","authenticated-orcid":false,"given":"G. Mani","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-5393","authenticated-orcid":false,"given":"Johan","family":"Auwerx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"4169_CR1","doi-asserted-by":"publisher","first-page":"14096","DOI":"10.1038\/s41598-018-32337-x","volume":"8","author":"L Kiss","year":"2018","unstructured":"Kiss, L. et al. The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta-analysis. Sci. Rep. 8, 14096 (2018).","journal-title":"Sci. Rep."},{"key":"4169_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","volume":"48","author":"J Scherer","year":"2014","unstructured":"Scherer, J., Singh, V., Pitchumoni, C. S. & Yadav, D. Issues in hypertriglyceridemic pancreatitis\u2014an update. J. Clin. Gastroenterol. 48, 195\u2013203 (2014).","journal-title":"J. Clin. Gastroenterol."},{"key":"4169_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019343","volume":"10","author":"S Saadatagah","year":"2021","unstructured":"Saadatagah, S. et al. Coronary heart disease risk associated with primary isolated hypertriglyceridemia; a population-based study. J. Am. Heart Assoc. 10, e019343 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"4169_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2013.10.004","volume":"18","author":"RJ Perry","year":"2013","unstructured":"Perry, R. J. et al. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metab. 18, 740\u2013748 (2013).","journal-title":"Cell Metab."},{"key":"4169_CR5","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","volume":"42","author":"R Quispe","year":"2021","unstructured":"Quispe, R. et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur. Heart J. 42, 4324\u20134332 (2021).","journal-title":"Eur. Heart J."},{"key":"4169_CR6","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels, B. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088\u20132093 (1998).","journal-title":"Circulation"},{"key":"4169_CR7","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.jlr.2021.100144","volume":"63","author":"O Kovrov","year":"2021","unstructured":"Kovrov, O., Landfors, F., Saar-Kovrov, V., N\u00e4slund, U. & Olivecrona, G. Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma. J. Lipid Res. 63, 100144 (2021).","journal-title":"J. Lipid Res."},{"key":"4169_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","volume":"78","author":"Z Ahmad","year":"2021","unstructured":"Ahmad, Z. et al. Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia. J. Am. Coll. Cardiol. 78, 193\u2013195 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4169_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/CRD.0000000000000258","volume":"27","author":"W Lang","year":"2019","unstructured":"Lang, W. & Frishman, W. H. Angiopoietin-like 3 protein inhibition: a new frontier in lipid-lowering treatment. Cardiol. Rev. 27, 211\u2013217 (2019).","journal-title":"Cardiol. Rev."},{"key":"4169_CR10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.23719","volume":"52","author":"BA Neuschwander-Tetri","year":"2010","unstructured":"Neuschwander-Tetri, B. A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52, 774\u2013788 (2010).","journal-title":"Hepatology"},{"key":"4169_CR11","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1194\/jlr.R066514","volume":"57","author":"ME Ertunc","year":"2016","unstructured":"Ertunc, M. E. & Hotamisligil, G. S. Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J. Lipid Res. 57, 2099\u20132114 (2016).","journal-title":"J. Lipid Res."},{"key":"4169_CR12","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/383728a0","volume":"383","author":"BA Janowski","year":"1996","unstructured":"Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R. & Mangelsdorf, D. J. An oxysterol signalling pathway mediated by the nuclear receptor LXR. Nature 383, 728\u2013731 (1996).","journal-title":"Nature"},{"key":"4169_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1073\/pnas.96.1.266","volume":"96","author":"BA Janowski","year":"1999","unstructured":"Janowski, B. A. et al. Structural requirements of ligands for the oxysterol liver X receptors LXR\u03b1 and LXR\u03b2. Proc. Natl Acad. Sci. USA 96, 266\u2013271 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4169_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/0022-2836(92)90411-C","volume":"225","author":"E Lolis","year":"1992","unstructured":"Lolis, E. et al. Preliminary crystallographic analysis of murine macrophage inflammatory protein 2. J. Mol. Biol. 225, 913\u2013915 (1992).","journal-title":"J. Mol. Biol."},{"key":"4169_CR15","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1101\/gad.850400","volume":"14","author":"JR Schultz","year":"2000","unstructured":"Schultz, J. R. et al. Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831\u20132838 (2000).","journal-title":"Genes Dev"},{"key":"4169_CR16","doi-asserted-by":"publisher","first-page":"11019","DOI":"10.1074\/jbc.M111041200","volume":"277","author":"SB Joseph","year":"2002","unstructured":"Joseph, S. B. et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277, 11019\u201311025 (2002).","journal-title":"J. Biol. Chem."},{"key":"4169_CR17","doi-asserted-by":"publisher","first-page":"E829","DOI":"10.1152\/ajpendo.00165.2005","volume":"289","author":"A Grefhorst","year":"2005","unstructured":"Grefhorst, A. et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob\/ob mice. Am. J. Physiol. Endocrinol. Metab. 289, E829\u2013E838 (2005).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"4169_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cmet.2016.07.016","volume":"24","author":"TG Kirchgessner","year":"2016","unstructured":"Kirchgessner, T. G. et al. Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils. Cell Metab. 24, 223\u2013233 (2016).","journal-title":"Cell Metab."},{"key":"4169_CR19","doi-asserted-by":"publisher","first-page":"1102469","DOI":"10.3389\/fmed.2023.1102469","volume":"10","author":"K Griffett","year":"2023","unstructured":"Griffett, K. & Burris, T. P. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases. Front. Med. 10, 1102469 (2023).","journal-title":"Front. Med."},{"key":"4169_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","volume":"21","author":"B Batchuluun","year":"2022","unstructured":"Batchuluun, B., Pinkosky, S. L. & Steinberg, G. R. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat. Rev. Drug Discov. 21, 283\u2013305 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4169_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/00041433-199606000-00002","volume":"7","author":"DJ Rader","year":"1996","unstructured":"Rader, D. J. & Ikewaki, K. Unravelling high density lipoprotein\u2013apolipoprotein metabolism in human mutants and animal models. Curr. Opin. Lipidol. 7, 117\u2013123 (1996).","journal-title":"Curr. Opin. Lipidol."},{"key":"4169_CR22","doi-asserted-by":"publisher","first-page":"28240","DOI":"10.1074\/jbc.M003337200","volume":"275","author":"P Costet","year":"2000","unstructured":"Costet, P., Luo, Y., Wang, N. & Tall, A. R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor\/retinoid X receptor. J. Biol. Chem. 275, 28240\u201328245 (2000).","journal-title":"J. Biol. Chem."},{"key":"4169_CR23","doi-asserted-by":"publisher","first-page":"10021","DOI":"10.1074\/jbc.M108225200","volume":"277","author":"CP Sparrow","year":"2002","unstructured":"Sparrow, C. P. et al. A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J. Biol. Chem. 277, 10021\u201310027 (2002).","journal-title":"J. Biol. Chem."},{"key":"4169_CR24","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1073\/pnas.112059299","volume":"99","author":"SB Joseph","year":"2002","unstructured":"Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 99, 7604\u20137609 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4169_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1021\/acschembio.2c00057","volume":"17","author":"K Griffett","year":"2022","unstructured":"Griffett, K. et al. Antihyperlipidemic activity of gut-restricted LXR inverse agonists. ACS Chem. Biol. 17, 1143\u20131154 (2022).","journal-title":"ACS Chem. Biol."},{"key":"4169_CR26","doi-asserted-by":"publisher","first-page":"e0249316","DOI":"10.1371\/journal.pone.0249316","volume":"16","author":"M Sengupta","year":"2021","unstructured":"Sengupta, M. et al. A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis. PLoS ONE 16, e0249316 (2021).","journal-title":"PLoS ONE"},{"key":"4169_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1021\/acsptsci.8b00003","volume":"1","author":"M Sengupta","year":"2018","unstructured":"Sengupta, M., Griffett, K., Flaveny, C. A. & Burris, T. P. Inhibition of hepatotoxicity by a LXR inverse agonist in a model of alcoholic liver disease. ACS Pharmacol. Transl. Sci. 1, 50\u201360 (2018).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"4169_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.molmet.2015.01.009","volume":"4","author":"K Griffett","year":"2015","unstructured":"Griffett, K. et al. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol. Metab. 4, 353\u2013357 (2015).","journal-title":"Mol. Metab."},{"key":"4169_CR29","doi-asserted-by":"publisher","first-page":"A12564","DOI":"10.1161\/circ.148.suppl_1.12564","volume":"148","author":"EJ Gane","year":"2023","unstructured":"Gane, E. J. et al. Safety, pharmacokinetics, and lipid lowering effects of the oral, liver-targeted liver X receptor (LXR) inverse agonist TLC-2716 in healthy volunteers. Circulation 148, A12564 (2023).","journal-title":"Circulation"},{"key":"4169_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41586-021-04103-z","volume":"599","author":"JD Backman","year":"2021","unstructured":"Backman, J. D. et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature 599, 628\u2013634 (2021).","journal-title":"Nature"},{"key":"4169_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203\u2013209 (2018).","journal-title":"Nature"},{"key":"4169_CR32","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/s42255-024-01126-4","volume":"6","author":"SM Lockhart","year":"2024","unstructured":"Lockhart, S. M. et al. Damaging mutations in liver X receptor-\u03b1 are hepatotoxic and implicate cholesterol sensing in liver health. Nat. Metab. 6, 1922\u20131938 (2024).","journal-title":"Nat. Metab."},{"key":"4169_CR33","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508\u2013518 (2023).","journal-title":"Nature"},{"key":"4169_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jclinepi.2015.09.016","volume":"70","author":"JM Gaziano","year":"2016","unstructured":"Gaziano, J. M. et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J. Clin. Epidemiol. 70, 214\u2013223 (2016).","journal-title":"J. Clin. Epidemiol."},{"key":"4169_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cels.2017.10.016","volume":"6","author":"H Li","year":"2018","unstructured":"Li, H. et al. An integrated systems genetics and omics toolkit to probe gene function. Cell Syst. 6, 90\u2013102 (2018).","journal-title":"Cell Syst."},{"key":"4169_CR36","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"GTEx Consortium.","year":"2013","unstructured":"GTEx Consortium. The Genotype\u2013Tissue Expression (GTEx) project. Nat. Genet. 45, 580\u2013585 (2013).","journal-title":"Nat. Genet."},{"key":"4169_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060107","volume":"6","author":"EE Schadt","year":"2008","unstructured":"Schadt, E. E. et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6, e107 (2008).","journal-title":"PLoS Biol."},{"key":"4169_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96966-5","volume":"11","author":"L Pantano","year":"2021","unstructured":"Pantano, L. et al. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci. Rep. 11, 18045 (2021).","journal-title":"Sci. Rep."},{"key":"4169_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba4448","volume":"12","author":"O Govaere","year":"2020","unstructured":"Govaere, O. et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci. Transl. Med. 12, eaba4448 (2020).","journal-title":"Sci. Transl. Med."},{"key":"4169_CR40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221738","volume":"220","author":"G Benegiamo","year":"2023","unstructured":"Benegiamo, G. et al. The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression. J. Exp. Med. 220, e20221738 (2023).","journal-title":"J. Exp. Med."},{"key":"4169_CR41","unstructured":"Gege, C. et al. LXR modulators with bicyclic core moiety. International patent WO2020002611A1 (2024)."},{"key":"4169_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3164\/jcbn.09-29","volume":"45","author":"F Takayama","year":"2009","unstructured":"Takayama, F. et al. A novel animal model of nonalcoholic steatohepatitis (NASH): hypoxemia enhances the development of NASH. J. Clin. Biochem. Nutr. 45, 335\u2013340 (2009).","journal-title":"J. Clin. Biochem. Nutr."},{"key":"4169_CR43","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0002-9440(10)63352-4","volume":"165","author":"C Tateno","year":"2004","unstructured":"Tateno, C. et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165, 901\u2013912 (2004).","journal-title":"Am. J. Pathol."},{"key":"4169_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cmet.2019.05.007","volume":"30","author":"R Ouchi","year":"2019","unstructured":"Ouchi, R. et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab. 30, 374\u2013384 (2019).","journal-title":"Cell Metab."},{"key":"4169_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46750-3","volume":"9","author":"L Fernandes Silva","year":"2019","unstructured":"Fernandes Silva, L., Vangipurapu, J., Kuulasmaa, T. & Laakso, M. An intronic variant in the GCKR gene is associated with multiple lipids. Sci. Rep. 9, 10240 (2019).","journal-title":"Sci. Rep."},{"key":"4169_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jhep.2024.08.009","volume":"82","author":"YJ Liu","year":"2025","unstructured":"Liu, Y. J. et al. ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD\/MASH. J. Hepatol. 82, 174\u2013188 (2025).","journal-title":"J. Hepatol."},{"key":"4169_CR47","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2337\/dc20-1787","volume":"44","author":"N Rasouli","year":"2020","unstructured":"Rasouli, N. et al. Association of baseline characteristics with insulin sensitivity and \u03b2-cell function in the Glycemia Reduction Approaches in Diabetes: a Comparative Effectiveness (GRADE) Study cohort. Diabetes Care 44, 340\u2013349 (2020).","journal-title":"Diabetes Care"},{"key":"4169_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2018.11.009","volume":"13","author":"JL Flores-Guerrero","year":"2019","unstructured":"Flores-Guerrero, J. L. et al. Lipoprotein insulin resistance index, a high-throughput measure of insulin resistance, is associated with incident type II diabetes mellitus in the Prevention of Renal and Vascular End-Stage Disease study. J. Clin. Lipidol. 13, 129\u2013137 (2019).","journal-title":"J. Clin. Lipidol."},{"key":"4169_CR49","first-page":"900","volume":"51","author":"ED Bischoff","year":"2010","unstructured":"Bischoff, E. D. et al. Non-redundant roles for LXR\u03b1 and LXR\u03b2 in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J. Lipid Res. 51, 900\u2013906 (2010).","journal-title":"J. Lipid Res."},{"key":"4169_CR50","doi-asserted-by":"publisher","first-page":"27816","DOI":"10.1074\/jbc.M603781200","volume":"281","author":"C Yang","year":"2006","unstructured":"Yang, C. et al. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J. Biol. Chem. 281, 27816\u201327826 (2006).","journal-title":"J. Biol. Chem."},{"key":"4169_CR51","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s10620-014-3289-x","volume":"59","author":"SB Ahn","year":"2014","unstructured":"Ahn, S. B., Jang, K., Jun, D. W., Lee, B. H. & Shin, K. J. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig. Dis. Sci. 59, 2975\u20132982 (2014).","journal-title":"Dig. Dis. Sci."},{"key":"4169_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56565-8","volume":"16","author":"AT Clark","year":"2025","unstructured":"Clark, A. T. et al. A mutation in LXR\u03b1 uncovers a role for cholesterol sensing in limiting metabolic dysfunction-associated steatohepatitis. Nat. Commun. 16, 1102 (2025).","journal-title":"Nat. Commun."},{"key":"4169_CR53","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0092-8674(00)81432-4","volume":"93","author":"DJ Peet","year":"1998","unstructured":"Peet, D. J. et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR\u03b1. Cell 93, 693\u2013704 (1998).","journal-title":"Cell"},{"key":"4169_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","volume":"126","author":"VT Samuel","year":"2016","unstructured":"Samuel, V. T. & Shulman, G. I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126, 12\u201322 (2016).","journal-title":"J. Clin. Invest."},{"key":"4169_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41854-2","volume":"9","author":"F Alam","year":"2019","unstructured":"Alam, F. et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. Sci. Rep. 9, 5389 (2019).","journal-title":"Sci. Rep."},{"key":"4169_CR56","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.111.063784","volume":"125","author":"KW Ng","year":"2012","unstructured":"Ng, K. W., Allen, M. L., Desai, A., Macrae, D. & Pathan, N. Cardioprotective effects of insulin. Circulation 125, 721\u2013728 (2012).","journal-title":"Circulation"},{"key":"4169_CR57","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark, B. A. et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N. Engl. J. Med. 390, 1770\u20131780 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4169_CR58","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne, C. M. et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N. Engl. J. Med. 391, 899\u2013912 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4169_CR59","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson, R. S. et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N. Engl. J. Med. 391, 913\u2013925 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4169_CR60","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","volume":"405","author":"BB Cummings","year":"2025","unstructured":"Cummings, B. B. et al. Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies. Lancet 405, 1923\u20131934 (2025).","journal-title":"Lancet"},{"key":"4169_CR61","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","volume":"85","author":"AT Nordestgaard","year":"2025","unstructured":"Nordestgaard, A. T. et al. Target populations for novel triglyceride-lowering therapies. J. Am. Coll. Cardiol. 85, 1876\u20131897 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4169_CR62","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.cgh.2016.03.034","volume":"14","author":"MT Long","year":"2016","unstructured":"Long, M. T. et al. Development and validation of the Framingham Steatosis Index to identify persons with hepatic steatosis. Clin. Gastroenterol. Hepatol. 14, 1172\u20131180 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"4169_CR63","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1053\/j.gastro.2020.10.002","volume":"160","author":"T Shinozawa","year":"2021","unstructured":"Shinozawa, T. et al. High-fidelity drug-induced liver injury screen using human pluripotent stem cell\u2013derived organoids. Gastroenterology 160, 831\u2013846 (2021).","journal-title":"Gastroenterology"},{"key":"4169_CR64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41588-023-01597-3","volume":"56","author":"R Cui","year":"2024","unstructured":"Cui, R. et al. Improving fine-mapping by modeling infinitesimal effects. Nat. Genet. 56, 162\u2013169 (2024).","journal-title":"Nat. Genet."},{"key":"4169_CR65","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","volume":"53","author":"U V\u00f5sa","year":"2021","unstructured":"V\u00f5sa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat. Genet. 53, 1300\u20131310 (2021).","journal-title":"Nat. Genet."},{"key":"4169_CR66","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"A Auton","year":"2015","unstructured":"Auton, A. et al. A global reference for human genetic variation. Nature 526, 68\u201374 (2015).","journal-title":"Nature"},{"key":"4169_CR67","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet. Epidemiol. 40, 304\u2013314 (2016).","journal-title":"Genet. Epidemiol."},{"key":"4169_CR68","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/aje\/kwt084","volume":"178","author":"BL Pierce","year":"2013","unstructured":"Pierce, B. L. & Burgess, S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am. J. Epidemiol. 178, 1177\u20131184 (2013).","journal-title":"Am. J. Epidemiol."},{"key":"4169_CR69","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 23, R89\u2013R98 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"4169_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"G Davey Smith","year":"2003","unstructured":"Davey Smith, G. & Ebrahim, S. \u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32, 1\u201322 (2003).","journal-title":"Int. J. Epidemiol."},{"key":"4169_CR71","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst"},{"key":"4169_CR72","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"4169_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"4169_CR74","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04169-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04169-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04169-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:02:39Z","timestamp":1774018959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04169-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4169"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04169-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.V., R.S.H., S.W., E.M., B.J.K., R.P.M. and G.M.S. are employed by OrsoBio, and J.A. and T.T. are advisors to OrsoBio. C.K. is employed by WM Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}